NAD+ and Menopause: What Every Woman Should Know About This Critical Connection

Menopause is one of the most significant biological transitions a woman will experience — and its effects extend far beyond the well-known hormonal changes. What is rarely discussed is that menopause and the perimenopause transition that precedes it create a perfect storm for NAD+ depletion, amplifying the cellular changes associated with normal ageing and driving many of the most disruptive symptoms women experience during this period.

Understanding this connection opens a new avenue for evidence-based support — one that addresses not just the symptoms of menopause but the cellular health foundation that determines how this transition is experienced.

The Menopause–NAD+ Connection: The Science

Oestrogen as a Regulator of NAD+ Biosynthesis

Oestrogen plays a direct role in regulating the enzymes involved in NAD+ production — particularly NAMPT, the rate-limiting enzyme in the main NAD+ biosynthesis pathway. Research published in Cell Reports (2019) demonstrated that oestrogen signalling supports NAMPT expression, and that oestrogen-deficient states are associated with significantly reduced NAMPT activity.

This means that as oestrogen levels decline during perimenopause and menopause, NAD+ biosynthesis is directly impaired — adding an endocrine-mediated acceleration to the normal age-related decline in NAD+ levels. The result: many women in their 40s and early 50s experience NAD+ depletion that is significantly faster and steeper than their male peers of equivalent age.

The CD38 Amplification Effect

As immune function shifts during the hormonal transition of menopause, the NAD+-consuming enzyme CD38 becomes increasingly active. CD38 is already a major driver of NAD+ depletion in normal ageing; during menopause, its accelerated activity compounds the already-compromised biosynthesis. The combination creates a double vulnerability that explains why many women report a sudden, dramatic shift in energy and vitality during this period — not merely a gradual age-related decline.

Mitochondrial Vulnerability During the Transition

Oestrogen is also a direct regulator of mitochondrial function, supporting mitochondrial biogenesis and protecting against oxidative stress. As oestrogen falls, mitochondria become more vulnerable, and NAD+ — already depleted — must work harder to support mitochondrial energy production with fewer resources. This is the cellular story behind the profound fatigue that characterises perimenopause for many women.

The NADvance pen delivers pharmaceutical-grade NAD+ subcutaneously — directly addressing the cellular energy and repair deficits that menopause accelerates. Explore at nadvance.eu/pages/pen

How Menopause Symptoms Map to NAD+ Depletion

Menopause Symptom	NAD+ Connection	Evidence Level
Fatigue and low energy	NAD+ required for mitochondrial ATP production	Strong
Brain fog and poor focus	Neuronal energy and SIRT1-mediated repair depend on NAD+	Strong
Sleep disruption	NAD+/SIRT1 regulates circadian molecular clock	Strong
Mood changes	Neuronal energy affects neurotransmitter balance	Moderate
Skin changes	NAD+ supports collagen-regulating sirtuin activity	Moderate
Metabolic changes	SIRT1/SIRT3 regulate insulin sensitivity and fat metabolism	Strong
Muscle weakness	Mitochondrial decline reduces ATP for muscle contraction	Strong

 

What NAD+ Therapy Offers Women in Menopause

NAD+ therapy does not replace oestrogen. It addresses a different — though closely related — biological deficit: the cellular energy and repair capacity that oestrogen partly regulated and that menopause compromises. The two approaches are complementary, not competing.

Energy and Vitality

By restoring NAD+ to therapeutic levels, mitochondrial ATP production improves, and the profound fatigue associated with menopause often lifts significantly. This is one of the most consistently reported benefits among women using NAD+ therapy during the perimenopausal and post-menopausal period.

Cognitive Support

Brain fog and cognitive changes are among the most distressing symptoms of menopause for many women. By supporting neuronal energy production and activating SIRT1-mediated neuroprotection, NAD+ therapy addresses the cellular root of these changes. Users frequently report improvements in focus, word retrieval, and mental endurance within the first 2–3 weeks.

Metabolic Resilience

The metabolic changes of menopause — increased insulin resistance, changes in body composition — are partly driven by the decline in sirtuin activity that accompanies both oestrogen loss and NAD+ depletion. Restoring NAD+ reactivates sirtuin pathways that support metabolic function, providing a meaningful contribution to metabolic health during this transition.

Skin and Cellular Renewal

Collagen synthesis, skin cell turnover, and protection against UV-induced skin damage are all influenced by NAD+-dependent processes. Women using NAD+ therapy frequently report improvements in skin quality — often describing skin as looking brighter, clearer, and more even in tone.

NAD+ Therapy and HRT: A Complementary Approach

Hormone Replacement Therapy (HRT) addresses the hormonal component of menopause directly. NAD+ therapy addresses the cellular energy and repair component. These are not competing interventions — they are complementary strategies that address different aspects of the same underlying biological transition.

Many women use both as part of a comprehensive approach to healthy ageing through menopause. If you are considering or currently using HRT, discussing NAD+ therapy with your healthcare provider is a sensible step to understand how the two approaches can work together.

Questions about NAD+ therapy during menopause? Our FAQ at nadvance.eu/pages/faq addresses common questions about concurrent use with HRT and other menopause treatments.

Frequently Asked Questions

Q: Does menopause really affect NAD+ levels? A: Yes, directly. Oestrogen supports the enzyme NAMPT, which drives NAD+ biosynthesis. As oestrogen declines during perimenopause, NAMPT activity falls, accelerating NAD+ depletion beyond the normal age-related rate. Research suggests women may experience steeper NAD+ decline during this transition than men of equivalent age.

 

Q: Can NAD+ therapy reduce menopause symptoms? A: Clinical evidence and user reports both indicate that NAD+ therapy can meaningfully improve energy, cognitive function, sleep quality, and metabolic health during the menopausal transition — all of which have a cellular energy and NAD+-dependent component. It does not address hot flushes or vasomotor symptoms, which are primarily hormonal.

 

Q: Can I use NAD+ therapy alongside HRT? A: Yes. NAD+ therapy and HRT address different biological mechanisms and are generally considered complementary. Always inform your healthcare provider of any new therapeutic interventions so they can be considered in the context of your overall health picture.

 

Q: When should women start NAD+ therapy — before or after menopause? A: The research suggests that NAD+ depletion begins accelerating during perimenopause, sometimes years before the official menopause threshold. Starting NAD+ therapy during perimenopause — when NAD+ levels are actively declining — may produce more pronounced early benefits than starting post-menopause.

Take proactive control of your cellular health through menopause. Order the NADvance pen at nadvance.eu/products/nadvance-pen-1000mg and begin with our step-by-step guide at nadvance.eu/pages/instructions.